Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionTrexquant Investment LP
Latest Disclosed Ownership307,136 shares
Latest Disclosed Value $ 3,817,700
Trexquant Investment LP ownership in AMRX / Amneal Pharmaceuticals, Inc.

On May 15, 2026 - Trexquant Investment LP filed a 13F-HR form disclosing ownership of 307,136 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $3,817,700 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2025 disclosing 0 shares of Amneal Pharmaceuticals, Inc.. The current value of the position is $4,223,120 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 307,136 307,136 3,818 0.0274
2025-11-14 2025-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -177,513 -100.00 0 -100.00
2025-08-12 2025-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 177,513 -452,838 -71.84 1,436 -72.81 0.0162
2025-05-14 2025-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 630,351 167,631 36.23 5,282 44.16 0.0614
2025-02-12 2024-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 462,720 223,158 93.15 3,665 83.84 0.0427
2024-11-12 2024-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 239,562 180,104 302.91 1,993 428.65 0.0252
2024-08-13 2024-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 59,458 -174,750 -74.61 378 -73.43 0.0058
2024-05-14 2024-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 234,208 223,570 2,101.62 1,419 2,117.19 0.0283
2024-02-09 2023-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 10,638 10,638 65 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.